Association between diabetes mellitus and multi-drug-resistant tuberculosis: evidence from a systematic review and meta-analysis

Balewgizie Sileshi Tegegne, Melkamu Merid Mengesha, Andreas A Teferra, Mamaru Ayenew Awoke, Tesfa Dejenie Habtewold, Balewgizie Sileshi Tegegne, Melkamu Merid Mengesha, Andreas A Teferra, Mamaru Ayenew Awoke, Tesfa Dejenie Habtewold

Abstract

Background: Diabetes mellitus (DM) poses a significant risk for the development of active tuberculosis (TB) and complicates its treatment. However, there is inconclusive evidence on whether the TB-DM co-morbidity is associated with a higher risk of developing multi-drug-resistant tuberculosis (MDR-TB). The aim of this meta-analysis was to summarize available evidence on the association of DM and MDR-TB and to estimate a pooled effect measure.

Methods: PubMed, Excerpta Medica Database (EMBASE), Web of Science, World Health Organization (WHO), and Global Health Library database were searched for all studies published in English until July 2018 and that reported the association of DM and MDR-TB among TB patients. To assess study quality, we used the Newcastle-Ottawa Scale for cohort and case-control studies and the Agency for Healthcare Research and Quality tool for cross-sectional studies. We checked the between-study heterogeneity using the Cochrane Q chi-squared statistic and I2 and examined a potential publication bias by visual inspection of the funnel plot and Egger's regression test statistic. The random-effect model was fitted to estimate the summary effects, odds ratios (ORs), and 95% confidence interval (CIs) across studies.

Results: This meta-analysis of 24 observational studies from 15 different countries revealed that DM has a significant association with MDR-TB (OR = 1.97, 95% CI = 1.58-2.45, I2 = 38.2%, P value for heterogeneity = 0.031). The significant positive association remained irrespective of country income level, type of DM, how TB or DM was diagnosed, and design of primary studies. A stronger association was noted in a pooled estimate of studies which adjusted for at least one confounding factor, OR = 2.43, 95% CI 1.90 to 3.12. There was no significant publication bias detected.

Conclusions: The results suggest that DM can significantly increase the odds of developing MDR-TB. Consequently, a more robust TB treatment and follow-up might be necessary for patients with DM. Efforts to control DM can have a substantial beneficial effect on TB outcomes, particularly in the case of MDR-TB.

Systematic review registration: PROSPERO CRD42016045692 .

Keywords: Diabetes mellitus; Meta-analysis; Multi-drug-resistant tuberculosis; Systematic review; Tuberculosis.

Conflict of interest statement

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Flow chart showing study selection process and search results
Fig. 2
Fig. 2
Forest plot showing the results of random effects meta-analysis of 24 observational studies. The horizontal line and vertical dotted line in the middle indicate the 95% confidence interval and its corresponding odds ratio (OR) estimate
Fig. 3
Fig. 3
Cumulative forest plot showing the results of random effects meta-analysis for the 24 observational studies on the association of DM and MDR-TB. The first row shows the effect based on one study, the second row shows the cumulative effect based on two studies, and so on
Fig. 4
Fig. 4
Funnel plot a and contour-enhanced funnel plot b of the included observational studies. In the contour-enhanced plot, the shaded region indicates areas of statistical significance, and non-statistical significance is represented in white. The vertical line corresponds to the summary log (OR) as estimated from the random-effect model (OR, odds ratio)

References

    1. World Health Organization . Global tuberculosis report 2017. Geneva: World Health Organization; 2017.
    1. World Health Organization . WHO end TB strategy: global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: WHO; 2015.
    1. Lönnroth K, Roglic G, Harries AD. Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. Lancet Diabetes Endocrinol. 2014;2:10. doi: 10.1016/S2213-8587(14)70109-3.
    1. Marais BJ, Lönnroth K, Lawn SD, Migliori GB, Mwaba P, Glaziou P, et al. Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control eff orts. Lancet Infect Dis 2013. 2013;13:13.
    1. IDF . IDF Diabetes ATLAS. 2013.
    1. Alkabab YM, Al-Abdely HM, Heysell SK. Diabetes-related tuberculosis in the Middle East: an urgent need for regional research. Int J Infect Dis. 2015;40:7. doi: 10.1016/j.ijid.2015.09.010.
    1. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008;5:e152. doi: 10.1371/journal.pmed.0050152.
    1. Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lönnroth K, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 2011;9:81. doi: 10.1186/1741-7015-9-81.
    1. World Health Organization . World Health Organization multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: WorldHealthOrganization; 2010.
    1. Nations JA, Lazarus AA, Walsh TE. Drug-resistant tuberculosis. Dis Mon. 2006;52:435–440. doi: 10.1016/j.disamonth.2006.09.008.
    1. Jain A, Dixit P. Multidrug resistant to extensively drug resistant tuberculosis: what is next? J Biosci. 2008;33:17. doi: 10.1007/s12038-008-0078-8.
    1. Ormerod LP. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br Med Bull. 2005;73-74:8. doi: 10.1093/bmb/ldh047.
    1. Kang YA, Kim SY, Jo KW, Kim HJ, Park SK, Kim TH, et al. Impact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosis. Respiration. 2013;86:7. doi: 10.1159/000348374.
    1. Chang J, Dou H, Yen C, Wu Y, Huang R, Lin H, et al. Effect of type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrug-resistance. J Formosan Med Assoc. 2011;110:10.
    1. Kameda K, Kawabata S, Masuda N. Follow-up study of short course chemotherapy of pulmonary tuberculosis complicated with diabetes mellitus. Kekkaku. 1990;65:13.
    1. Park S, Shin J, Kim J, Park I, Choi B, Choi J, et al. The effect of diabetic control status on the clinical features of pulmonary tuberculosis. Eur J Clin Microbiol Infect Dis. 2012;31:6.
    1. Baghaei P, Marjani M, Javanmard P, Tabarsi P, Masjedi MR. Diabetes mellitus and tuberculosis facts and controversies. J Diabetes Metab Disord. 2013;12(1):58. doi: 10.1186/2251-6581-12-58.
    1. Bashar M, Alcabes P, Rom WN, Condos R. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. CHEST Journal. 2001;120:6. doi: 10.1378/chest.120.5.1514.
    1. Pérez-Navarro LM, Fuentes-Domínguez FJ, Zenteno-Cuevas R. Type 2 diabetes mellitus and its influence in the development of multidrug resistance tuberculosis in patients from southeastern Mexico. J Diabetes Complicat. 2015;29:6. doi: 10.1016/j.jdiacomp.2014.09.007.
    1. Rifat M, Milton AH, Hall J, Oldmeadow C, Islam MA, Husain A, et al. Development of multidrug resistant tuberculosis in Bangladesh: a case-control study on risk factors. PLoS One. 2014;9:e105214. doi: 10.1371/journal.pone.0105214.
    1. Suarez-Garcia I, Rodriguez-Blanco A, Vidal-Perez J, Garcia-Viejo M, Jaras-Hernandez M, Lopez O, et al. Risk factors for multidrug-resistant tuberculosis in a tuberculosis unit in Madrid, Spain. Eur J Clin Microbiol Infect Dis. 2009;28:6. doi: 10.1007/s10096-008-0627-y.
    1. Bendayan D, Hendler A, Polansky V, Weinberger M. Outcome of hospitalized MDR-TB patients: Israel 2000–2005. Eur J Clin Microbiol Infect Dis. 2011;30:5. doi: 10.1007/s10096-010-1096-7.
    1. Gómez-Gómez A, Magaña-Aquino M, López-Meza S, Aranda-Álvarez M, Díaz-Ornelas DE, Hernández-Segura MG, et al. Diabetes and other risk factors for multi-drug resistant tuberculosis in a Mexican population with pulmonary tuberculosis: case control study. Arch Med Res. 2015;46:7. doi: 10.1016/j.arcmed.2015.01.006.
    1. Kikvidze M, Mikiashvili L. Impact of diabetes mellitus on drug-resistant tuberculosis treatment outcomes in Georgia-cohort study. Eur Respir J. 2013;42.
    1. Baghaei P, Tabarsi P, Chitsaz E, Novin A, Alipanah N, Kazempour M, et al. Risk factors associated with multidrug-resistant tuberculosis. TANAFFOS-Journal of Respiratory Disease, Thoracic Surgery Intensive Care and Tuberculosis. 2009;8:5.
    1. Baghaei P, Tabarsi P, Abrishami Z, Mirsaeidi M, Faghani YA, Mansouri SD, et al. Comparison of pulmonary TB patients with and without diabetes mellitus type II. Tanaffos. 2010;9:8.
    1. Singla R, Khan N, Al-Sharif N, Al-Sayegh M, Shaikh M, Osman M. Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. The International Journal of Tuberculosis and Lung Disease. 2006;10:6.
    1. Tanrikulu AC, Hosoglu S, Ozekinci T, Abakay A, Gurkan F. Risk factors for drug resistant tuberculosis in southeast Turkey. Trop Dr. 2008;38:4.
    1. Liu Q, Li W, Xue M, Chen Y, Du X, Wang C, et al. Diabetes mellitus and the risk of multidrug resistant tuberculosis: a meta-analysis. Sci Rep. 2017;7(1):1090. doi: 10.1038/s41598-017-01213-5.
    1. Perez-Navarro LM, Restrepo BI, Fuentes-Dominguez FJ, Duggirala R, Morales-Romero J, López-Alvarenga JC, et al. The effect size of type 2 diabetes mellitus on tuberculosis drug resistance and adverse treatment outcomes. Tuberculosis. 2017;103:9. doi: 10.1016/j.tube.2017.01.006.
    1. Magee M, Bloss E, Shin S, Contreras C, Huaman HA, Ticona JC, et al. Clinical characteristics, drug resistance, and treatment outcomes among tuberculosis patients with diabetes in Peru. Int J Infect Dis. 2013;17:e404–ee12. doi: 10.1016/j.ijid.2012.12.029.
    1. Hafez S, Elhefnawy A, Hatata E, El Ganady A, Ibrahiem M. Detection of extensively drug resistant pulmonary tuberculosis. Egyptian Journal of Chest Diseases and Tuberculosis. 2013;62:12. doi: 10.1016/j.ejcdt.2013.07.012.
    1. Salindri AD, Kipiani M, Kempker RR, Gandhi NR, Darchia L, Tukvadze N, et al. Diabetes reduces the rate of sputum culture conversion in patients with newly diagnosed multidrug-resistant tuberculosis. Open Forum Infect Dis. 2016;3(3):ofw126. doi: 10.1093/ofid/ofw126.
    1. Carreira S, Costeira J, Gomes C, André J, Diogo N. Impact of diabetes on the presenting features of tuberculosis in hospitalized patients. Rev Port Pneumol (English Edition) 2012;18((5)):239–243.
    1. Saktiawati AMI, Subronto YW. Influence of diabetes mellitus on the development of multi-drug resistant-tuberculosis in Yogyakarta. Indones J Intern Med. 2018;50(1):7.
    1. Tegegne BS, Habtewold TD, Mengesha MM, Burgerhof JG. Association between diabetes mellitus and multi-drug-resistant tuberculosis: a protocol for a systematic review and meta-analysis. Syst Rev. 2017;6:6. doi: 10.1186/s13643-017-0407-9.
    1. Beller EM, Glasziou PP, Altman DG, Hopewell S, Bastian H, Chalmers I, et al. PRISMA for abstracts: reporting systematic reviews in journal and conference abstracts. PLoS Med. 2013;10:e1001419. doi: 10.1371/journal.pmed.1001419.
    1. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. PLoS Med. 2010;7:e1000217. doi: 10.1371/journal.pmed.1000217.
    1. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D. Meta-analysis of observational studies in epidemiology. A Proposal for Reporting JAMA. 2000;283(15):5.
    1. Wells G, Shea B, O’connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000.
    1. Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8:9. doi: 10.1111/jebm.12141.
    1. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:30.
    1. Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:30. doi: 10.1002/sim.1186.
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:11. doi: 10.1016/0197-2456(86)90046-2.
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:5.
    1. Tob’ıas A. sbe26 Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;47:3.
    1. StataCorp . Stata Statistical Software: Release 14. College Station: StataCorp LP; 2015.
    1. Hsu A, Lee J, Chiang C, Li Y, Chen L, Lin C. Diabetes is associated with drug-resistant tuberculosis in Eastern Taiwan. Int J Tuberc Lung Dis. 2013;17:13. doi: 10.5588/ijtld.11.0670.
    1. Mi F, Jiang G, Du J, Li L, Yue W, Harries AD, et al. Is resistance to anti-tuberculosis drugs associated with type 2 diabetes mellitus? A register review in Beijing, China. Glob Health Action. 2014;7:24022. doi: 10.3402/gha.v7.24022.
    1. Fisher-Hoch SP, Whitney E, McCormick JB, Crespo G, Smith B, Rahbar MH, et al. Type 2 diabetes and multidrug-resistant tuberculosis. Scand J Infect Dis. 2008;40:6. doi: 10.1080/00365540802342372.
    1. Zhang Q, Xiao H, Sugawara I. Tuberculosis complicated by diabetes mellitus at Shanghai Pulmonary Hospital. China Jpn J Infect Dis. 2009;62:12.
    1. Min Jinhong, Park Keeho, Whang Suhee, Kim Jinhee. Risk Factors for Primary Multidrug Resistant Tuberculosis. Tuberculosis and Respiratory Diseases. 2005;59(6):600. doi: 10.4046/trd.2005.59.6.600.
    1. Magee MJ, Kempker RR, Kipiani M, Gandhi NR, Darchia L, ea TN. Diabetes mellitus is associated with cavities, smear grade, and multidrug-resistant tuberculosis in Georgia. Int J Tuberc Lung Dis. 2015;19:8. doi: 10.5588/ijtld.14.0811.
    1. Jitmuang A, Munjit P, Foonglada S. Prevalence and factors associated with multidrug-resistant tuberculosis at Siriraj Hospital, Bangkok, Thailand. Southeast Asian J Trop Med Public Health. 2015;46:10.
    1. Workneh MH, Bjune GA, Yimer SA. Prevalence and associated factors of tuberculosis and diabetes mellitus comorbidity: a systematic review. PLoS One. 2017;12:e0175925. doi: 10.1371/journal.pone.0175925.
    1. Al-Rifai RH, Pearson F, Critchley JA, Abu-Raddad LJ. Association between diabetes mellitus and active tuberculosis: a systematic review and meta-analysis. PLoS One. 2017;12:e0187967. doi: 10.1371/journal.pone.0187967.
    1. Voils CI, Crandell JL, Chang Y, Leeman J, Sandelowski M. Combining adjusted and unadjusted findings in mixed research synthesis. J Eval Clin Pract. 2011;17(3):10. doi: 10.1111/j.1365-2753.2010.01444.x.
    1. World Health Organization, and International Union against Tuberculosis and Lung Disease . Collaborative framework for care and control of tuberculosis and diabetes. Geneva: World Health Organization; 2011.

Source: PubMed

3
구독하다